Novo Nordisk A/S

NVO | News | $128.64 2.7% -0.07% 3.7M

(0.0% 1d) (-2.9% 1m) (-26.5% 1y) (0.0% 2d) (0.0% 3d) (0.6% 7d) (-26.72% volume)
Earnings Calendar:
Market Cap: $ 441,894,865,920
http://www.novonordisk.com
Sec Filling | Patents | 43258 employees

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

obesity diabetes haemophilia insulin diabetic hormone growth hormone

add to watch list Paper trade email alert is off

Press-releases

Novo Nordisk A/S - share repurchase programme
Published: 2024-04-22 (Crawled : 13:00) - globenewswire.com
NVO | News | $128.64 2.7% -0.07% 3.7M

Health Technology

| 2.08% | O: -0.1% H: 2.99% C: 2.18%
repurchase

SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients
Published: 2024-04-22 (Crawled : 18:00) - biospace.com/
NVO | News | $128.64 2.7% -0.07% 3.7M

Health Technology

| 2.08% | O: -0.1% H: 2.99% C: 2.18%
snipr001 cancer trials funding

Peptide Therapeutics Market Projected to Reach $57.97 billion by 2030 - Exclusive Report by 360iResearch
Published: 2024-04-19 (Crawled : 15:00) - prnewswire.com
AZNCF | News | $138.73 -4.19% 3.7K

Health Technology

| 2.53% | O: 0.24% H: 0.42% C: 0.42%
NVO | News | $128.64 2.7% -0.07% 3.7M

Health Technology

| 0.59% | O: -0.84% H: 0.86% C: -0.62%
GSK | News | $41.24 1.6% 0.0% 2.3M

Health Technology

| 2.5% | O: -0.56% H: 0.0% C: 0.0%
LLY | News | $745.69 1.96% -0.16% 2M

Health Technology

| -2.59% | O: -0.21% H: 0.11% C: -3.05%
AZN | News | $70.85 1.03% 1.02% 5.6M

Health Technology

| 2.73% | O: -0.18% H: 0.84% C: 0.6%
report reach therapeutics market

Ventus Therapeutics Announces Results from Phase 1 Clinical Trial of VENT-02, a Novel, Orally Administered, Brain-Penetrant NLRP3 Inhibitor
Published: 2024-04-17 (Crawled : 14:00) - biospace.com/
NVO | News | $128.64 2.7% -0.07% 3.7M

Health Technology

| 1.47% | O: 1.22% H: 0.21% C: -0.34%
vent-02 trial therapeutics results

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Published: 2024-04-15 (Crawled : 18:00) - globenewswire.com
NVO | News | $128.64 2.7% -0.07% 3.7M

Health Technology

| 0.6% | O: 1.04% H: 0.19% C: -1.52%

Novo Nordisk A/S - share repurchase programme
Published: 2024-04-15 (Crawled : 13:00) - globenewswire.com
NVO | News | $128.64 2.7% -0.07% 3.7M

Health Technology

| 0.6% | O: 1.04% H: 0.19% C: -1.52%
repurchase

Novo Nordisk A/S - share repurchase programme
Published: 2024-04-08 (Crawled : 13:30) - globenewswire.com
NVO | News | $128.64 2.7% -0.07% 3.7M

Health Technology

| 0.23% | O: 1.62% H: 0.5% C: 0.36%
repurchase

Ventus Therapeutics to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference
Published: 2024-04-08 (Crawled : 12:30) - biospace.com/
NVO | News | $128.64 2.7% -0.07% 3.7M

Health Technology

| 0.23% | O: 1.62% H: 0.5% C: 0.36%
conference therapeutics

REDUCED secures EUR 6 million financing led by Novo Holdings to scale its natural food ingredients business
Published: 2024-04-04 (Crawled : 06:00) - prnewswire.com
NVO | News | $128.64 2.7% -0.07% 3.7M

Health Technology

| -0.2% | O: 1.1% H: 0.46% C: -2.32%
business natural million food

2023 Novo Holdings Asia Investments Annual Review/Business Update
Published: 2024-04-03 (Crawled : 07:00) - prnewswire.com
NVO | News | $128.64 2.7% -0.07% 3.7M

Health Technology